REG - N4 Pharma PLC - N4 Pharma’s Nuvec® Targets Lung Cancer Cells

N4 PharmaAnnouncement

22/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250922:nRSV0555Aa&default-theme=true

RNS Number : 0555A  N4 Pharma PLC  22 September 2025

 

22 September 2025

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

 

N4 Pharma's Nuvec® Targets Lung Cancer Cells

Proof of targeted RNA delivery to non-small cell lung cancer cells achieved
with SRI

 

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary
gene delivery system to enable advanced therapies for cancer and other
diseases, is pleased to announce further details of its collaboration with
world-renowned nonprofit R&D institute SRI on the targeted delivery of RNA
into cells using Nuvec®. Following detailed additional analysis, the
resulting data are now shaping a new scope of work focused on
utilising Nuvec® for targeted treatments in oncology.

 

The Company's collaboration combined SRI's targeting molecules with Nuvec®
successfully delivering therapeutic RNA ("siRNA") payloads to specific cell
types, specifically non-small cell lung cancer cells.

 

Key results:

 

·    Precision targeting achieved: Nuvec® particles were functionalised
with a targeting molecule binding to a cell surface adhesion molecule (αvβ6)
- a protein found at high levels in epithelial cancers such as lung, breast,
prostate and pancreatic adenocarcinomas

·    Selective uptake confirmed: siRNA payloads were successfully
delivered and active only by the targeted Nuvec® particles compared to
untargeted Nuvec®, demonstrating that Nuvec® can be directed to specific
cell types

·    Broader validation of Nuvec®: The findings strengthen the platform's
potential as a differentiated delivery system for RNA therapeutics across
multiple disease areas, including cancers of high unmet need such as lung and
pancreatic cancers

 

The global RNA therapeutics market was valued at $13.7 billion in 2023 and is
forecast to reach $18.0 billion by 2028. Challenges associated with the
manufacturing and targeted delivery of RNA therapeutics are known to impact
this market growth.

 

Targeting RNA therapies to specific cells and tissues to maximise efficacy and
reduce systemic toxicity is a holy grail for nucleic acid therapeutics
developers and is challenging to achieve with established RNA delivery
methods.

 

In parallel to the successful targeting of Nuvec® particles to cancer cells
in collaboration with SRI, N4 Pharma has also demonstrated targeting of
Nuvec® to immune cells using mannose modification in its lead programme, N4
101, which is designed to be an orally delivered treatment for inflammatory
bowel disease.

 

Nigel Theobold, Chief Executive Officer of N4 Pharma, commented:

 

"Targeting RNA therapies to particular cell types is highly sought after by
companies developing RNA therapeutics. We have now demonstrated Nuvec®'s
ability to do this in multiple systems, which we believe sets it apart from
other RNA delivery methods.

 

"These recent data from our collaboration with SRI are particularly exciting
because they represent the first example of the use of Nuvec® for the
potential treatment of some of the most common and life-threatening cancers.

 

"N4 Pharma raised capital earlier this year to build out the data to support
the key performance claims of Nuvec®: simultaneous delivery of multiple RNAs;
targeting of specific cell types; oral delivery; low immunogenicity;
stability; and simple manufacturing. These data generated with SRI are a
significant step forward in that process, because of the high demand for
targeted therapies to support deal-making and building our own differentiated
RNA therapeutics pipeline."

 

- Ends -

 

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                                       Via N4 Pharma Investor Hub: investors.n4pharma.com

                                                                         (https://investors.n4pharma.com/)
 Luke Cairns, Executive Director

                                                                         https://n4pharma.com/link/P2z1YP (https://n4pharma.com/link/P2z1YP)
 Submit your questions directly to the management team via the N4 Pharma

 Investor Hub
 SP Angel Corporate Finance LLP                                            Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Jen Clarke (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                                     Tel: +44 (0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope
 Northstar Communications Limited                                          Tel: +44 (0)113 730 3896

 Investor Relations

 Sarah Hollins

 

About N4 Pharma

 

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its
proprietary gene delivery system, to enable advanced therapies for cancer and
other diseases.

 

RNA therapeutics are set to impact the treatment of a wide range of diseases
and Nuvec® has several key advantages for RNA gene delivery including the
ability to deliver multiple RNA therapies in a single particle, ease of
manufacturing, protection of the RNA payload to allow for oral delivery, no
unwanted immune response and excellent stability and storage.

 

N4 Pharma is building out its preclinical data set and working towards
first-in-human clinical data to support significant licensing deals for its
Nuvec® platform with gene therapy partners.

 

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for
IBD which serves as a proof-of-concept programme showcasing all the benefits
of the Nuvec® platform.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at
https://investors.n4pharma.com/auth/signup
(https://investors.n4pharma.com/auth/signup) .

 

About SRI

 

For further information on SRI visit: https://www.sri.com/
(https://www.sri.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCZZGMLNLLGKZG



            Copyright 2019 Regulatory News Service, all rights reserved